Cardiovascular Disease Doctors in Mayfield Heights, OH Accepting Medicare

3 Cardiovascular Disease doctors found. Showing 1 - 3

Dr. Deirdre J Mattina, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6780 Mayfield Rd, Mayfield Heights, OH 44124 Phone: 440-312-4500

Mrs. Frances Emily Devlin, PA Internal Medicine - Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 6801 Mayfield Rd, Mayfield Heights, OH 44124 Phone: 440-312-4500

Thomas Mark Sequeira, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6803 Mayfield Rd, Suite 412, Mayfield Heights, OH 44124 Phone: 440-442-7300    Fax: 440-442-9019

News Archive

Poor nutrition, health cause disparities in fetal growth and newborn size worldwide

Babies' growth in the womb and their size at birth, especially their length, are strikingly similar the world over - when babies are born to healthy, well-educated and well-nourished mothers.

Self-destructive mitochondria may set the stage for neurodegeneration in ALS

Northwestern Medicine scientists have discovered a new phenomenon in the brain that could explain the development of early stages of neurodegeneration seen in diseases such as ALS, which affects voluntary muscle movement such as walking and talking.

Techulon signs exclusive license with Virginia Tech to market new theranostic transfection reagent

Techulon™ Inc., an early stage life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new theranostic transfection reagent. This new traceable reagent complements Techulon's currently marketed Glyocofect™ transfection platform and expands the company's offering in an $800 million market that is steadily growing at 15% annually.

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.

CNS cancer survivors have greater neurocognitive dysfunction than survivors of other types of cancer

Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors - the most common solid malignancies in childhood - shows that survivors have ongoing cognitive problems.

Read more Medical News

› Verified 9 days ago